slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 39,031-39,060
Pages 10,126
Rows per page 30
Component
39,031-39,060 of 303,780
15
Includes 2001-2020 averages for both metrics.Lindsay Corporation | Results Presentation Deck | 17 slides · Lindsay Corporation
Conference presentation Investor relations Beat · Action2 hits
01
Features a Louis Vuitton branded image.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations 2 hits
04
The chart illustrates the bridge between 44,177 million euros in 9M 2021 and 56,485 million euros in 9M 2022.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Beat · AttentionLoop · Logic Chain2 hits
08
Part of a Q3 2022 revenue presentation.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain2 hits
09
The chart uses a standard waterfall bridge to explain the variance between two periods.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain2 hits
11
The slide serves as a visual transition between business group reviews.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain2 hits
14
The slide uses a high-end aesthetic typical of luxury brand presentations.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain2 hits
15
The chart shows a bridge from 4,668 million euros to 5,577 million euros.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain2 hits
17
The slide uses a high-impact celebrity endorsement image to brand the business group.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain2 hits
18
The chart illustrates the bridge between 6,160 million euros and 7,575 million euros.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain2 hits
20
The slide serves as a visual transition for the 'Business Groups Review' section.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain2 hits
21
The chart illustrates a bridge from 7,795 million euros to 10,095 million euros.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain2 hits
01
Includes ticker symbols MNSB & MNSBP and date October 2022.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Attention2 hits
31
MainStreet Bancshares | Results Presentation Deck | 31 slidesMainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Action2 hits
01
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 2 hits
03
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 2 hits
10
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 2 hits
15
The slide uses a process-flow diagram to present five key clinical findings.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Traction2 hits
19
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Traction2 hits
25
The slide highlights clinical safety and pharmacokinetic success for an oral formulation of amikacin.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 2 hits
07
The chart shows a 15.1% decrease in Q3 2022 volume compared to Q3 2021.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 2 hits
08
The chart compares quarterly container volumes between 2021 and 2022.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 2 hits
09
Includes a footnote regarding 4Q21 volume benefit from a 53rd week.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 2 hits
10
The chart shows quarterly operating income for 2021 and 2022, with Q3 2022 highlighted as a range.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 2 hits
09
Includes definitions of acronyms and citations for preclinical studies.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
13
NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); T2DM (Type 2 Diabetes Mellitus); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
15
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
17
The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
18
Study uses male DIO-NASH mice with 30-week GAND feeding and 9-week treatment regimen.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
04
Includes a molecular visualization of the inhibitor binding to the protein.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 2 hits